Literature DB >> 8958166

The toxic shock syndromes.

D L Stevens1.   

Abstract

Because of the frequency with which Staphylococcus aureus and Streptococcus pyogenes infections occur, physicians are quite familiar with the diversity of their clinical presentations. In the 1970s, however, shock associated with multiorgan failure was described in menstruating female patients as well as in male patients following a variety of surgical procedures, such as rhinoplasty. This previously undescribed presentation of S. aureus infection, termed staphylococcal toxic shock syndrome, was associated with unique strains of S. aureus. In the mid-1980s, the emergence of streptococcal toxic shock syndrome was heralded by several case reports describing patients with group A streptococcal infections associated with shock and organ failure. This article compares the differences in the epidemiologic, clinical, and pathophysiologic features of the toxic shock syndromes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8958166     DOI: 10.1016/s0891-5520(05)70324-x

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  14 in total

1.  Therapeutic Approaches to Streptococcal Toxic Shock Syndrome.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

2.  Caspase inhibitors attenuate superantigen-induced inflammatory cytokines, chemokines, and T-cell proliferation.

Authors:  Teresa Krakauer
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

3.  Modulation of endotoxin- and enterotoxin-induced cytokine release by in vivo treatment with beta-(1,6)-branched beta-(1,3)-glucan.

Authors:  J Soltys; M T Quinn
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

Review 4.  Toxic shock syndrome in children: epidemiology, pathogenesis, and management.

Authors:  Yu-Yu Chuang; Yhu-Chering Huang; Tzou-Yien Lin
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

5.  Impact of Currently Marketed Tampons and Menstrual Cups on Staphylococcus aureus Growth and Toxic Shock Syndrome Toxin 1 Production In Vitro.

Authors:  Louis Nonfoux; Myriam Chiaruzzi; Cédric Badiou; Jessica Baude; Anne Tristan; Jean Thioulouse; Daniel Muller; Claire Prigent-Combaret; Gérard Lina
Journal:  Appl Environ Microbiol       Date:  2018-05-31       Impact factor: 4.792

6.  Rapamycin protects mice from staphylococcal enterotoxin B-induced toxic shock and blocks cytokine release in vitro and in vivo.

Authors:  Teresa Krakauer; Marilyn Buckley; Haleem J Issaq; Stephen D Fox
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

7.  Proinflammatory mediators of toxic shock and their correlation to lethality.

Authors:  Teresa Krakauer; Marilyn J Buckley; Diana Fisher
Journal:  Mediators Inflamm       Date:  2010-06-16       Impact factor: 4.711

8.  One in five mortality in non-menstrual toxic shock syndrome versus no mortality in menstrual cases in a balanced French series of 55 cases.

Authors:  E Descloux; T Perpoint; T Ferry; G Lina; M Bes; F Vandenesch; I Mohammedi; J Etienne
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01       Impact factor: 3.267

Review 9.  Superantigens in human disease.

Authors:  A Bernal; T Proft; J D Fraser; D N Posnett
Journal:  J Clin Immunol       Date:  1999-05       Impact factor: 8.542

10.  Intranasal rapamycin rescues mice from staphylococcal enterotoxin B-induced shock.

Authors:  Teresa Krakauer; Marilyn Buckley
Journal:  Toxins (Basel)       Date:  2012-09-18       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.